Navigation Links
EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
Date:6/4/2009

VIENNA, Austria, June 4 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical, the pharmaceutical, and other industries, announced today that it has successfully launched its first commercial enzyme, a beta-lactamase. The product is manufactured by EUCODIS Bioscience and can be supplied in a GMP-compliant formulation. The Company will market its beta-lactamase to antibiotics manufacturers to improve quality control, to the diagnostics industry, and to research organizations. The Company estimates that its beta-lactamase has a market potential of up to EUR 5 million.

"The launch of a beta-lactamase for the antibiotics industry and other uses opens a new phase in the development of our organization," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "The EUCODIS Bioscience team has demonstrated its capacity to cover the whole value-chain of an integrated enzyme supplier, from enzyme development, to manufacturing, and to marketing. This success adds momentum to our efforts to bring to market further products that we are currently developing. We will continue to provide our development expertise and our technology to industrial partners that want to increase their research and development efficiency."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:

    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:

    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Signs Research Agreement With Genencor
2. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
3. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
4. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
5. Regado Biosciences Establishes Medical Advisory Board
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
7. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
8. Universite de Montreal and Validapro Biosciences Inc. have Signed an Agreement-in-Principle
9. YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
10. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
11. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
Breaking Biology News(10 mins):